Sarepta Therapeutics (SRPT) News Today

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares ticked up modestly today amid a mix of analyst updates and mounting legal headwinds. Investors are weighing a bullish Seeking Alpha thesis and a Bank of America price-target increase against growing short interest, debt-refinancing reactions, and multiple class-action lawsuits.

• Positive Sentiment: Bank of America raises SRPT price target to $17, citing potential upside despite an “underperform” rating. Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Bank of America Analyst Says
• Positive Sentiment: A Seeking Alpha analysis highlights SRPT as a strong buying opportunity amid market pullbacks. Sarepta Therapeutics: A Strong Opportunity Amidst The Panic
• Neutral Sentiment: Sarepta restructures $700 million of convertible notes, exchanging existing debt for new senior notes due 2028. Sarepta Therapeutics Restructures Debt with New Convertible Notes
• Negative Sentiment: Multiple law firms—including Levi & Korsinsky, Rosen, Hagens Berman and others—have filed or reminded investors of pending class-action lawsuits against SRPT with an August 25 deadline, creating legal overhang. Levi & Korsinsky Reminds Sarepta Therapeutics Investors of the Pending Class Action Lawsuit
• Negative Sentiment: Short interest jumps 41% in July, now representing over 23% of SRPT’s float, indicating bearish investor positioning. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest Update
• Negative Sentiment: BofA Securities lowers SRPT price target amid concerns over near-term catalysts. Sarepta Therapeutics (SRPT): B of A Securities Lowers Price Target
• Negative Sentiment: SRPT shares dipped following the announcement of the convertible note refinancing, reflecting investor concern over dilution. Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027